Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT04191486 is registered in ClinicalTrials.gov with FUJIFILM Toyama Chemical Co., Ltd. as lead sponsor.

NCT NCT04191486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04191486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 24, 2019
Completion date
March 20, 2023
Enrollment
221 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment